

REFERENCES:

1. Bird TD. Charcot-Marie-Tooth (CMT) Hereditary Neuropathy Overview. 1998 Sep 28 [Updated 2021 Sep 9]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1358/>
2. Braathen GJ. Genetic epidemiology of Charcot-Marie-Tooth disease. *Acta Neurol Scand.* 2012;126:iv-22.
3. DiVincenzo C, Elzinga CD, Medeiros AC, et al. The allelic spectrum of Charcot-Marie-Tooth disease in over 17,000 individuals with neuropathy. *Mol Genet Genomic Med.* 2014;2(6):522-9.
4. Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. *Nat Rev Neurol.* 2013;9(10):562-71.
5. Drew AP, Zhu D, Kidambi A, et al. Improved inherited peripheral neuropathy genetic diagnosis by whole-exome sequencing. *Mol Genet Genomic Med.* 2015;3(2):143-54.
6. Dohrn MF, Glöckle N, Mulahasanovic L, et al. Frequent genes in rare diseases: panel-based next generation sequencing to disclose causal mutations in hereditary neuropathies. *J Neurochem.* 2017;143(5):507-22.
7. Cortese A, Wilcox JE, Polke JM, Poh R, Skorupinska M, Rossor AM, Laura M, Tomaselli PJ, Houlden H, Shy ME, Reilly MM. Targeted next-generation sequencing panels in the diagnosis of Charcot-Marie-Tooth disease. *Neurology.* 2020;94(1):51-61.
8. Felice KJ, Whitaker CH, Khorasanizadeh S. Diagnostic yield of advanced genetic testing in patients with hereditary neuropathies: A retrospective single-site study. *Muscle & Nerve.* 2021;64(4):454-61.
9. Saghira C, Bis DM, Stanek D, et al. Variant pathogenicity evaluation in the community-driven Inherited Neuropathy Variant Browser. *Hum Mutat.* 2018;39(5):635-42.
10. Werheid F, Azzedine H, Zwerenz E, et al. Underestimated associated features in CMT neuropathies: clinical indicators for the causative gene?. *Brain Behav.* 2016;6(4):1-14.
11. McCray BA, Scherer SS. Axonal Charcot-Marie-Tooth Disease: from Common Pathogenic Mechanisms to Emerging Treatment Opportunities. *Neurotherapeutics.* 2021;18(4):2269-85.
12. Dorn GW. Mitofusin 2 Dysfunction and Disease in Mice and Men. *Front Physiol.* 2020;11:1-9.
13. Abati E, Manini A, Velardo D, et al. Clinical and genetic features of a cohort of patients with MFN2-related neuropathy. *Sci Rep.* 2022;12(1):61-81.
14. Filadi R, Pendin D, Pizzo P. Mitofusin 2: from functions to disease. *Cell Death Dis.* 2018;9(3):1-13.

15. Beręsewicz M, Charzewski Ł, Krzyśko KA, Kochoński A, Zabłocka B. Molecular modelling of mitofusin 2 for a prediction for Charcot-Marie-Tooth 2A clinical severity. *Sci Rep.* 2018;8(1):1-9.
16. Pipis M, Feely SME, Polke JM, et al. Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study. *Brain.* 2020;143(12):3589-602.
17. Nan H, Hata T, Fukao T, et al. MFN2-related Charcot-Marie-Tooth Disease with Atypical Ocular Manifestations. *Intern Med.* 2021;60(24):3969-74.
18. Guerriero S, D'Oria F, Rossetti G, et al. CMT2A Harboring Mitofusin 2 Mutation with Optic Nerve Atrophy and Normal Visual Acuity. *IMCRJ.* 2020;Volume 13:41-5.
19. Li Y, Aleman TS, Quinn CC, et al. Charcot-Marie-Tooth Disease Associated With a Novel Mutation in MFN2 Presenting With Subacute Vision Loss. *Journal of Neuro-Ophthalmology.* 2022;42(1):e381-e384.
20. Kimura Y, Nishikawa A, Hashiguchi A, et al. An MFN2-related Charcot-Marie-Tooth Disease Patient with Optic Nerve Atrophy, Neurogenic Bladder Dysfunction, and Diaphragmatic Weakness. *Intern Med.* [published online ahead of print: November 20, 2021]. 10.2169/internalmedicine.6487-20.
21. Wu R, Fu J, Meng L, Lv H, Wang Z, Yuan Y. Late-onset hereditary sensory and autonomic neuropathy expands the phenotypic spectrum of MFN2 -related diseases. *Neuropathology.* 2018;38(5):463-7.
22. Verhoeven K. MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. *Brain.* 2006;129(8):2093-102.
23. Calvo J, Funalot B, Ouvrier RA, et al. Genotype-Phenotype Correlations in Charcot-Marie-Tooth Disease Type 2 Caused by Mitofusin 2 Mutations. *Arch Neurol.* 2009;66(12).
24. Feely SME, Laura M, Siskind CE, et al. MFN2 mutations cause severe phenotypes in most patients with CMT2A. *Neurology.* 2011;76(20):1690-6.
25. Mou Y, Dein J, Chen Z, Jagdale M, Li X. MFN2 Deficiency Impairs Mitochondrial Transport and Downregulates Motor Protein Expression in Human Spinal Motor Neurons. *Front Mol Neurosci.* 2021;14:1-11.